.avif)
.avif)
Passage BIO Email Format
Biotechnology Research
・
51-200 employees
・
Philadelphia, PA, USA
Passage BIO is a clinical-stage genetic medicines company developing one-time therapies to treat neurodegenerative diseases by targeting underlying disease pathology.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@passagebio.com
Company Overview
Industry
Biotechnology Research
Founded
2017
Headquarters
Philadelphia, PA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
William Chou (President and Chief Executive Officer), Kathleen Borthwick (Chief Financial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Passage BIO?
Passage BIO uses the firstinitiallast format on passagebio.com, so Jane Smith would be jsmith@passagebio.com.
What CNS diseases does Passage BIO's PBFT02 program target?
PBFT02 is Passage BIO's lead gene therapy program targeting frontotemporal dementia, amyotrophic lateral sclerosis, and Alzheimer's disease, with a focus on patients who carry specific mutations or variants linked to low progranulin protein levels in the CNS.
Which university research partnership supports Passage BIO's gene therapy discovery work?
Passage BIO has a strategic collaboration and licensing agreement with the University of Pennsylvania's Gene Therapy Program, which supports the company's discovery and IND-enabling preclinical work for its CNS pipeline.
How many people work at Passage BIO?
Passage BIO has 52 employees and is headquartered in Philadelphia, PA. Tools like Clay can help you identify and verify the right contacts at Passage BIO when building a targeted outreach list.
Did Passage BIO out-license any of its programs to other companies?
In August 2024, Passage BIO out-licensed three pediatric gene therapy programs, PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy, to GEMMA Biotherapeutics, which received exclusive worldwide rights to develop and commercialize them.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating